跳至主要内容
临床试验/ISRCTN17621057
ISRCTN17621057进行中(未招募)未知

The dynamics of epigenetic, metabolic and endocrine alterations during critical illness: a prospective cross-sectional study

KU Leuven0 个研究点目标入组 374 人开始时间: 2015年12月9日最近更新:

试验速览

阶段
未知
状态
进行中(未招募)
发起方
KU Leuven
入组人数
374

研究概览

简要总结

2022 Interim results article in https://pubmed.ncbi.nlm.nih.gov/35584557/ (added 17/08/2023)

研究设计

研究类型
Observational

入排标准

性别
All

入选标准

  • 1. Patients:
  • All adult/senior patients at the surgical and medical intensive care units are eligible
  • 2. Controls:
  • A control group of volunteers who have not been critically ill, but have similar comorbidities as the critically ill patients will be recruited to match demographically with the patient group

排除标准

  • 1. Patients:
  • 1.1. General:
  • 1.1.1. Age younger than 18 years
  • 1.1.2. Readmission to ICU (unless within 48 hrs)
  • 1.1.3. Declined participation
  • 1.1.4. DNR code
  • 1.1.5. Patients with HIV
  • 1.1.6. Chronic systemic treatment with glucocorticoids prior to ICU admission (added 12/09/2018: patients who did receive chronic systemic treatment with glucocorticoids prior to ICU admission will be recruited separately to allow investigation of the impact of prior chronic systemic glucocorticoid treatment)
  • 1.2. Blood sampling: absence of arterial line
  • 1.3. Mouth mucosa sampling: normal mouth mucosa not accessible (e.g. post-tumor resection)
  • 1.4. Neuromuscular evaluation:
  • 1.4.1. General:
  • 1.4.1.1. Patients with neuromuscular disorders identified prior to ICU admission / unable to walk without assistance (wheelchair, walking stick, arm support) prior to ICU admission
  • 1.4.1.2. Patients with a neuromuscular disorder as reason for ICU admission
  • 1.4.2. Muscle biopsy: increased bleeding risk
  • 1.4.2.1. Platelet count below 50000/mm3 and/or PT below 40%
  • 1.4.2.2. Known coagulation disorders
  • 1.4.2.3. Use of anti-coagulation or thrombolytic agents
  • 1.4.3. Muscle force by MRC sum score:
  • 1.4.3.1. No muscle biopsy
  • 1.4.3.2. Patient not awake/cooperative (*)
  • 1.4.4. Hand grip strength
  • 1.4.4.1. No muscle biopsy
  • 1.4.4.2. Patients not awake/cooperative (*)
  • 1.4.4.4. Medical Research Council (MRC) score for forearm flexion or wrist extension below 3
  • 1.4.5. Electromyography / nerve conduction studies / direct muscle stimulation
  • 1.4.5.1. No muscle biopsy
  • (*) patients who give a biopsy but are not awake/cooperative at the time of sampling will be screened for awakening/cooperation up until two days later for MRC sum scoring and hand grip strength
  • 1.5. Fat biopsy: increased bleeding risk:
  • 1.5.1. Platelet count below 50000/mm3 and/or PT below 40%
  • 1.5.2. Known coagulation disorders
  • 1.5.3. Use of anti-coagulation or thrombolytic agents
  • 2. Controls:
  • 2.1. General
  • 2.1.1. Age younger than 18 years
  • 2.1.2. Previous ICU stay (except coronary care unit stay)
  • 2.2. Blood sampling: known severe coagulation disorders (e.g. hemophilia)
  • 2.3. Mouth mucosa sampling: normal mouth mucosa not accessible (e.g. post-tumor resection)
  • 2.4. Muscle and fat biopsy:
  • 2.4.1. Controls with acute or chronic neuromuscular disorders or unable to walk without assistance (wheelchair, walking stick, arm support) will be excluded for muscle biopsy
  • 2.4.2. Increased risk of bleeding:
  • 2.4.2.1. Known coagulation disorders
  • 2.4.2.2. Use of anti-coagulation
  • 2.5. Muscle force / electrophysiology / direct muscle stimulation: no muscle biopsy

研究者

发起方
KU Leuven

相似试验